Neuromyelitis optica: Concepts in evolution

Journal of Neuroimmunology

Volumn 231, Issue 1-2, 2011, Pages 100-104

  Fazio, Raffaella ^a   Radaelli, Marta ^a   Furlan, Roberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Aquaporin 4; Devic's disease; Multiple sclerosis; Myelitis; Neuromyelitis optica; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; ASIAN; ASTROCYTE; CLINICAL FEATURE; DISEASE SEVERITY; EARLY DIAGNOSIS; GLIA; HUMAN; JAPANESE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; OPTIC NERVE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SPINAL CORD; VISUAL DISORDER;

ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; BIOLOGICAL EVOLUTION; HUMANS; NEUROMYELITIS OPTICA; PROGNOSIS;

EID: 79952449289     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.10.012     Document Type: Article

References (55)

1. Acchiote P. Sur un cas de neuromyélite subaiguë ou maladie de Devic. Rev. Neurol. 1907, 15:775-777.
2. Adoni T., Lino A.M., da Gama P.D., Apostolos-Pereira S.L., Marchiori P.E., Kok F., Callegaro D. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult. Scler. 2010, 16:81-86.
3. Allbutt T.C. On the ophtalmoscopic signs of spinal disease. Lancet 1870, 95:76-78.
4. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., Glogowska M., Case D., Antel J.P., Owens G.P., Gilden D., Nessler S., Stadelmann C., Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
5. Bingley P.J., Bonifacio E., Mueller P.W. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003, 52:1128-1136.
6. Bizzoco E., Lolli F., Repice A.M., Hakiki B., Falcini M., Barilaro A., Taiuti R., Siracusa G., Amato M.P., Biagioli T., Lori S., Moretti M., Vinattieri A., Nencini P., Massacesi L., Mata S. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J. Neurol. 2009, 256:1891-1898.
7. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
8. Cabrera-Gomez J.A., Bonnan M., Gonzalez-Quevedo A., Saiz-Hinarejos A., Marignier R., Olindo S., Graus F., Smadja D., Merle H., Thomas L., Gomez-Garcia A., Cabre P. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult. Scler. 2009, 15:828-833.
9. Collongues N., Marignier R., Zephir H., Papeix C., Blanc F., Ritleng C., Tchikviladze M., Outteryck O., Vukusic S., Fleury M., Fontaine B., Brassat D., Clanet M., Milh M., Pelletier J., Audoin B., Ruet A., Lebrun-Frenay C., Thouvenot E., Camu W., Debouverie M., Creange A., Moreau T., Labauge P., Castelnovo G., Edan G., Le Page E., Defer G., Barroso B., Heinzlef O., Gout O., Rodriguez D., Wiertlewski S., Laplaud D., Borgel F., Tourniaire P., Grimaud J., Brochet B., Vermersch P., Confavreux C., de Seze J. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010, 74:736-742.
10. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
11. Devic E. Myélite aiguë dorso-lombaire avec névrite optique. Congrès français de médecine 1894, Vol. 1:434-439. Lyon.
12. Devic E. Myélite subaiguë compliquée de névrite optique. Bull. Méd. 1894, 8:1033-1034.
13. Erb W. Ueber das Zusammenvorkommen von Neuritis optica und Myelitis subacuta. Arch. Psychiatr. Nervenkr. 1880, 10:146-157.
14. Fazio R., Malosio M.L., Lampasona V., De Feo D., Privitera D., Marnetto F., Centonze D., Ghezzi A., Comi G., Furlan R., Martino G. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult. Scler. 2009, 15:1153-1163.
15. Gault F. De la neuromyélite optique aiguë, Neurology Vol. PhD 1894, University of Lyon, Lyon.
16. Ghezzi A., Bergamaschi R., Martinelli V., Trojano M., Tola M.R., Merelli E., Mancardi L., Gallo P., Filippi M., Zaffaroni M., Comi G. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J. Neurol. 2004, 251:47-52.
17. Hayakawa S., Mori M., Okuta A., Kamegawa A., Fujiyoshi Y., Yoshiyama Y., Mitsuoka K., Ishibashi K., Sasaki S., Hattori T., Kuwabara S. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J. Neuroimmunol. 2008, 196:181-187.
18. Hazin R., Khan F., Bhatti M.T. Neuromyelitis optica: current concepts and prospects for future management. Curr. Opin. Ophthalmol. 2009, 20:434-439.
19. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., Kryzer T.J., Lennon V.A. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
20. Hinson S.R., Roemer S.F., Lucchinetti C.F., Fryer J.P., Kryzer T.J., Chamberlain J.L., Howe C.L., Pittock S.J., Lennon V.A. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 2008, 205:2473-2481.
21. Hinson S.R., McKeon A., Fryer J.P., Apiwattanakul M., Lennon V.A., Pittock S.J. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 2009, 66:1164-1167.
22. Jarius S., Franciotta D., Bergamaschi R., Wright H., Littleton E., Palace J., Hohlfeld R., Vincent A. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
23. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., Lang W., Reindl M., Vincent A., Kristoferitsch W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
24. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., Vincent A., Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 2008, 4:202-214.
25. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., Kumanogoh A., Kajiyama K., Yoshikawa H., Sakoda S. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem. Biophys. Res. Commun. 2010, 394:205-210.
26. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003, 2:117-127.
27. Kira J. Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann. NY Acad. Sci. 2008, 1142:58-71.
28. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J. Med. 2007, 356:371-378.
29. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
30. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
31. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
32. Matiello M., Lennon V.A., Jacob A., Pittock S.J., Lucchinetti C.F., Wingerchuk D.M., Weinshenker B.G. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008, 70:2197-2200.
33. Matsuoka T., Matsushita T., Kawano Y., Osoegawa M., Ochi H., Ishizu T., Minohara M., Kikuchi H., Mihara F., Ohyagi Y., Kira J. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007, 130:1206-1223.
34. Nicchia G.P., Mastrototaro M., Rossi A., Pisani F., Tortorella C., Ruggieri M., Lia A., Trojano M., Frigeri A., Svelto M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57:1363-1373.
35. O'Riordan J.I., Gallagher H.L., Thompson A.J., Howard R.S., Kingsley D.P., Thompson E.J., McDonald W.I., Miller D.H. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 1996, 60:382-387.
36. Papais-Alvarenga R.M., Miranda-Santos C.M., Puccioni-Sohler M., de Almeida A.M., Oliveira S., Basilio De Oliveira C.A., Alvarenga H., Poser C.M. Optic neuromyelitis syndrome in Brazilian patients. J. Neurol. Neurosurg. Psychiatry 2002, 73:429-435.
37. Paul F., Jarius S., Aktas O., Bluthner M., Bauer O., Appelhans H., Franciotta D., Bergamaschi R., Littleton E., Palace J., Seelig H.P., Hohlfeld R., Vincent A., Zipp F. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007, 4:e133.
38. Pittock S.J., Lennon V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 2008, 65:629-632.
39. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 2006, 63:390-396.
40. Pittock S.J., Weinshenker B.G., Lucchinetti C.F., Wingerchuk D.M., Corboy J.R., Lennon V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 2006, 63:964-968.
41. Rivera J.F., Kurtzke J.F., Booth V.J., Corona V.T.T. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J. Neurol. 2008, 255:710-715.
42. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., Mandler R.N., Weinshenker B.G., Pittock S.J., Wingerchuk D.M., Lucchinetti C.F. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
43. Saadoun S., Papadopoulos M.C. Aquaporin-4 in brain and spinal cord oedema. Neuroscience 2010, 168:1036-1046.
44. Saiz A., Zuliani L., Blanco Y., Tavolato B., Giometto B., Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J. Neurol. 2007, 254:1233-1237.
45. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., Watanabe S., Shiga Y., Kanaoka C., Fujimori J., Sato S., Itoyama Y. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235-1243.
46. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
47. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., Antel J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 2008, 181:5730-5737.
48. Watanabe S., Nakashima I., Misu T., Miyazawa I., Shiga Y., Fujihara K., Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 2007, 13:128-132.
49. Waters P., Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int. MS J. 2008, 15:99-105.
50. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., Geraldes R., Vale T., Jacob A., Palace J., Maxwell S., Beeson D., Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 2008, 65:913-919.
51. Weinshenker B.G., Wingerchuk D.M., Vukusic S., Linbo L., Pittock S.J., Lucchinetti C.F., Lennon V.A. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 2006, 59:566-569.
52. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
53. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
54. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
55. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.